Search

Atopic dermatitis (AD), a chronic and inflammatory skin disease, has brought huge physiological and psychological burdens to patients, which causes wide concerns in society. Herein, a multifunctional microneedle (MN) patch is proposed integrated with a desirable moisturizer and intelligent drug delivery capacity for AD treatment. Such MN patch consists of hyaluronic acid (HA) backing and near‐infrared (NIR) responsive tips containing black phosphorous quantum dots (BPQDs), low‐melting agarose, polyvinylpyrrolidone (PVP), and triamcinolone acetonide (TA). Among them, the soluble HA serves as a long‐term moisturizer for relieving dryness symptoms of AD. By introducing the NIR excitable and photothermal responsive BPQDs into agarose, the state of the composite material can be adjusted intelligently via NIR, thus achieving controllable release of the encapsulated TA in tips. Besides, PVP with enough mechanical strength can help MNs successfully penetrate the thickened skin of AD patients. Based on these advantages, it is demonstrated that the multifunctional MN patch reveals a satisfactory therapeutic effect in the AD model of Balb/c mice. These results indicate the potential values of the proposed MN patch in the treatment of AD skin diseases and other related biomedical fields. [ABSTRACT FROM AUTHOR]

An inflammation-responsive double-layer microneedle patch could be responsively degraded by atopic dermatitis specific inflammatory factor MMP to release loaded Vitamin D 3 for recurrent AD therapy. [Display omitted] Seeking a potent therapeutic strategy for alleviating atopic dermatitis (AD) attack and preventing its recurrence is highly desired but remains challenging in clinical practice. Here, we propose an inflammation-responsive double-layer microneedle (IDMN) patch in situ delivering VD 3 for recurrent AD therapy. IDMN comprises the backing layer part and the double-layer microneedle part, in which the inner layer is gelatin methacryloyl (GelMA) loaded with VD 3 while the outer layer is composed of hyaluronic acid (HA). Introduction of the HA backing layer and outer layer around the GelMA tips can not only provide sufficient mechanical strength to penetrate into hardened AD skin with minimal invasiveness, but also exert a strong moisturizing effect after being rapidly dissolved. The inner layer of GelMA is degraded by the matrix metalloproteinase (MMP) in a dose dependent manner, which is secreted according to the disease progression of AD. The responsive degradation of GelMA tips result in corresponding release of VD 3 to treat AD, triggering negative feedback against GelMA degradation. The IDMN administration on AD-bearing mice reveals efficient "curing" performances (including suppress erythema, scaling and lichenification, reduce epidermal thickness, inhibit mast cells infiltration, and down-regulate inflammatory factor secretion), which are basically realized through synergistic effect of the released VD 3 and the dissolved HA molecules. Importantly, the residual tips of IDMN with VD 3 are retained in the skin after the first AD relief, showing promising "warning" ability to inhibit the recurrence of AD. Hence, the developed IDMN patch is expected to be one of the excellent candidates for AD therapy and other relapsing diseases in clinical fields. [ABSTRACT FROM AUTHOR]